ReviewFrontiers in endocrinology2019
Insulin Resistance in Patients With Acromegaly.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women.Clinical endocrinology · 2025Guideline
- ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.The Journal of clinical endocrinology and metabolism · 2023Trial
- The relationships among nutrition, body composition, muscle strength and physical performance in patients with acromegaly.Archives of endocrinology and metabolism · 2026Observational
- Acromegaly complications: an update.The Journal of clinical endocrinology and metabolism · 2026Review
- Consensus on acromegaly complications: an update.Pituitary · 2026Article
- Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.Pituitary · 2026Article
- Preoperative Metabolic Predictors of Granulation Subtypes in Somatotroph Tumors: A Multicenter Retrospective Cohort Study.CNS neuroscience & therapeutics · 2026Article
- Case Report: Treatment of hypersomatotropism in a diabetic dog with transsphenoidal hypophysectomy.Frontiers in veterinary science · 2026Article
- Acromegaly and colorectal cancer risk: emerging roles of the gut microbiota.Frontiers in endocrinology · 2026Review
- Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer.Biomolecules · 2025Review
- The 20 kDa isoform of the human growth hormone variant alters adipose and muscle gene expression differently than human growth hormone.Journal of neuroendocrinology · 2025Article
- Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism.Journal of endocrinological investigation · 2025Review
- Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal.Frontiers in endocrinology · 2024Review
- How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.Endocrine · 2023Review
- Long-term Outcome of Body Composition, Ectopic Lipid, and Insulin Resistance Changes With Surgical Treatment of Acromegaly.Journal of the Endocrine Society · 2023Article
- The potential utility of the SAGIT instrument in the clinical assessment of patients with acromegaly, a large single-centre study.Scientific reports · 2023Article
- The Impact of Westernization on the Insulin/IGF-I Signaling Pathway and the Metabolic Syndrome: It Is Time for Change.International journal of molecular sciences · 2023Review
- Polycystic ovary syndrome preceding the diagnosis of acromegaly: a retrospective study in 97 reproductive-aged women.Reproductive biology and endocrinology : RB&E · 2023Article
- Uric acid levels correlate with disease activity in growth hormone-secreting pituitary adenoma patients.Frontiers in endocrinology · 2023Article
- Insulin Requirements in Untreated Acromegaly: From 200 to 0.JCEM case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly is characterized by chronic overproduction of growth hormone (GH) that leads to insulin resistance, glucose intolerance and, ultimately, diabetes. The GH-induced sustained stimulation of lipolysis plays a major role not only in the development of insulin resistance and prediabetes/diabetes, but also in the reduction of lipid accumulation, making acromegaly a unique case of severe insulin resistance in the presence of reduced body fat. In the present review, we elucidate the effects of GH hypersecretion on metabolic organs, describing the pathophysiology of impaired glucose tolerance in acromegaly, as well as the impact of acromegaly-specific therapies on glucose metabolism. In addition, we highlight the role of insulin resistance in the development of acromegaly-associated complications such as hypertension, cardiac disease, sleep apnea, polycystic ovaries, bone disease, and cancer. Taken together, insulin resistance is an important metabolic hallmark of acromegaly, which is strongly related to disease activity, the development of comorbidities, and might even impact the response to drugs used in the treatment of acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.